70 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
7 May 24
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
7:39am
Statements of Operations Data:
Operating Expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other … . The Company estimates that it has sufficient cash to fund operations and capital expenditures through the second quarter of 2025.
Research
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
of 2025.
Research and development expenses were $37.2 million for the year ended December 31, 2023, compared to $30.3 million for 2022. The increase … data)
For the Year Ended December 31,
Consolidated Statements of Operations Data:
Operating Expenses:
Research and development
General and administrative
8-K
rgwkgccgu
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
424B5
c3bakfh74 6pkdnc2pg
13 Mar 24
Prospectus supplement for primary offering
4:04pm
424B5
k61kjcc8ol0kx0l9
11 Mar 24
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
t6nw 9qym6gvauwjlna7
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
2a5r2uyw5z yrt
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
33ar44oyn2evfo m4i
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
S-3
n4g6u wnw
23 Dec 22
Shelf registration
4:16pm
8-K
EX-99.1
q58r81
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
h5hosti
14 Nov 22
Prospectus supplement with pricing info
6:02am